Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Sorafenib 52pembrolizumab 26Nivolumab 20Bevacizumab 19Radiosurgery 17Doxorubicin 12atezolizumab 9Erlotinib Hydrochloride 9lenvatinib 8cabozantinib 7Magnetic Resonance Spectroscopy 7tremelimumab 6durvalumab 6Ramucirumab 6Radiofrequency Ablation 6Cisplatin 6Sunitinib 5tislelizumab 4regorafenib 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Fluorouracil 4Everolimus 4Capecitabine 4nintedanib 3fluoromisonidazole 3carotuximab 3bavituximab 3Tomography, X-Ray Computed 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Hepatocellular × FS 069 × Clear all
NCT03199274 2026-01-02

Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer

Thomas Jefferson University

Phase 2 Completed
104 enrolled 8 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡